SPAG9 and nonpapillary renal cell carcinoma: Reduced SPAG9 expression was significantly associated with clinical-stage progression (Stage I vs. Stage IV), primary tumor enlargement (T1 vs. T4), and tumor metastasis (N0 vs. N1 and M0 vs. M1) in the ccRCC patients (p value < 0.05, Figure 1B).